Compare · AZN vs SHPH
AZN vs SHPH
Side-by-side comparison of AstraZeneca PLC (AZN) and Shuttle Pharmaceuticals Holdings Inc. (SHPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and SHPH operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $257.39B, about 66641.1x SHPH ($3.9M).
- Over the past year, AZN is down 11.9% and SHPH is down 89.0% - AZN leads by 77.1 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 5 for SHPH).
- AZN has more recent analyst coverage (25 ratings vs 0 for SHPH).
- Company
- AstraZeneca PLC
- Shuttle Pharmaceuticals Holdings Inc.
- Price
- $165.88+0.80%
- $3.71-4.87%
- Market cap
- $257.39B
- $3.9M
- 1M return
- -1.44%
- +19.29%
- 1Y return
- -11.90%
- -88.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2022
- News (4w)
- 12
- 5
- Recent ratings
- 25
- 0
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
- SVP, Group Controller Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,267 units (SEC Form 4)
- SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
Latest SHPH
- SEC Form NT 10-Q filed by Shuttle Pharmaceuticals Holdings Inc.
- Amendment: Shuttle Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form DEF 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- SEC Form PRE 14A filed by Shuttle Pharmaceuticals Holdings Inc.
- Large owner Hrt Financial Lp sold $372,704 worth of shares (83,149 units at $4.48), closing all direct ownership in the company (SEC Form 4)
- Large owner Hrt Financial Lp bought $30,212 worth of shares (8,997 units at $3.36), increasing direct ownership by 17% to 61,271 units (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 60,540 shares (SEC Form 3)
- Large owner Hrt Financial Lp sold $100,461 worth of shares (29,111 units at $3.45), decreasing direct ownership by 36% to 52,274 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $27,793 worth of shares (7,851 units at $3.54) and sold $31,667 worth of shares (9,022 units at $3.51), decreasing direct ownership by 1% to 81,385 units (SEC Form 4)